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Metastasis-Associated Protein 1 Nuclear Expression is
Associated with Tumor Progression and Clinical Outcome
in Patients with Non-small Cell Lung Cancer
Xiaoxia Zhu, MD,* Yu Guo, MD,† Xiangzhao Li, BMed,‡ Yanqing Ding, MMed,‡
and Longhua Chen, MMed*
Introduction: Little research has been done to test the usefulness of
metastasis-associated protein 1 (MTA1) as a prognostic marker for
non-small cell lung cancer (NSCLC). In this study, we investigated
MTA1 expression and its prognostic value for NSCLC.
Methods: NSCLC surgical tissue samples were taken from 100
patients with NSCLC who had been followed up for more than 2
years. The expression of MTA1 protein was evaluated by immu-
nohistochemistry, and the correlations between the expression of
MTA1 and clinical features and the prognosis were analyzed. The
difference of MTA1 protein expression between NSCLCs and
their adjacent nonneoplastic lung tissues was analyzed in a tissue
microarray. The change of MTA1 mRNA expression and protein
expression after RNA interference (RNAi) was detected by real-
time polymerase chain reaction, Western blot, and immunocyto-
chemistry in NSCLC cell line 95D.
Results: Overexpression of MTA1 (immunoreactivity scoring 4)
was shown in 61.0% of the NSCLC cases but only in 9.4% of their
adjacent nonneoplastic lung tissues (p  0.001). The MTA1 expres-
sion level was correlated with lymph node metastasis (p  0.013)
and clinical stage (p  0.002). Survival analysis showed that the
MTA1 overexpression group had a significantly shorter overall
survival time than the MTA1 downexpression group (p  0.003).
However, multivariate analysis showed that MTA1 expression was
not a significant and independent prognostic parameter for patients
with NSCLC. After RNAi, the 95D cells exhibit consistent reduction
in MTA1 mRNA expression and MTA1 protein expression.
Conclusion: MTA1 protein expression is associated with tumor
progression and clinical outcome in patients with NSCLC. Further
molecular, cellular, and animal model studies on MTA1 gene will
provide new clues for exploring the mechanism of carcinogenesis
and tumor progression in patients with NSCLC.
Key Words: MTA1, NSCLC, Immunohistochemical analysis, Me-
tastasis, Prognosis.
(J Thorac Oncol. 2010;5: 1159–1166)
Lung cancer is a serious threat to human health and life and isknown as world’s leading killer. Both the morbidity and
mortality of lung cancer head the list in the malignant tumors.
With the aggravation of air pollution, the morbidity of lung
cancer showed a marked increase. Non-small cell lung cancer
(NSCLC) accounts for about 80% of all lung cancer. Despite
progresses in diagnosis and therapy has been made recently, the
prognosis of lung cancer remains very poor, and the 5-year
cumulative survival rate is less than 15%. Cancer metastasis is
the major cause of death in patients with lung cancer.
Metastasis is a complex disease involving a series of
events that includes stimulation or repression of numerous
gene products in a coordinate manner, resulting in the inva-
sion of neoplastic cells and detachment from the primary
tumors, penetration into blood and lymphatics, arrest by
adhesion at distant sites, extravasation, induction of angio-
genesis, evasion of host antitumor responses, and growth at
metastatic sites.1
The role of metastasis-associated proteins (MTAs) fam-
ily of coregulators in transcriptional programs has aroused
wide concern recently.2,3 MTA are integral parts of nucleo-
some remodeling and histone deacetylation (NuRD) com-
plexes.4,5 MTA family members exist in distinct NuRD com-
plexes,6 and functional redundancy is lacking among MTA
family members. MTA proteins regulate divergent cellular
pathways, including hormonal action, epithelial-to-mesen-
chymal transitions, differentiation, protein stability and de-
velopment, and cell fate programs by modifying the acetyla-
tion status of crucial target genes.2
MTA1, the founding member of the MTA family of
genes, was originally identified through differential screening of
a cDNA library from rat metastatic breast tumors.7 Subsequent
studies found a widespread upregulation of MTA1 in human
tumors.8 MTA1 is closely associated with the carcinogenesis
and metastasis of many human carcinomas, including endome-
trial adenocarcinomas, gastrointestinal carcinoids, colorectal
carcinoma and hepatocellular carcinoma, esophageal squamous
cell carcinoma, prostate cancer, thymomas, etc.9–15
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Recently, researches16,17 have suggested that MTA1 is
closely associated with frequent postoperative recurrence and
poor survival in patients with hepatocellular carcinoma or
breast cancer. However, the potential prognostic relevance of
MTA1 expression in NSCLC has not yet been investigated.
In this study, we attempted to investigate the expression
of MTA1 in NSCLC using immunohistochemical analysis,
identify its relationship with clinicopathological features, and
evaluate its prognostic value in respect of survival in patients
with NSCLC.
PATIENTS AND METHODS
Patients and Tissue Samples
A total of 100 patients with NSCLC, who had under-
gone routine surgery at Nangfang Hospital, Guangzhou City,
Guangdong Province, China from January 2002 and Decem-
ber 2006, were enrolled in our retrospective study. They were
not pretreated with radiotherapy or chemotherapy before
surgery. The patients were followed up for a median period of
25.1 months (range, 1.4–59.3 months) after operation, and
their complete clinical data were collected. All NSCLC
samples taken from the 100 patients were fixed in 10%
formalin, embedded in paraffin, sectioned consecutively at 4
m, and stained by hematoxylin and eosin. All tumors were
classified according to World Health Organization classifica-
tion,18 and the staging of the tumor was done according to the
international staging system.19 The study was approved by
the Ethical Committee of Nanfang Hospital of Southern
Medical University, and written informed consent was ob-
tained from each patient. All samples were made anonymous,
and none of the researchers conducting the experiments in the
study had access to clinicopathological data.
The tissue microarray consisted of 64 NSCLC samples,
and their adjacent nonneoplastic lung tissues was obtained
from Outdo Biotech CO. Ltd. (ShangHai, China).
Immunohistochemical Staining
The sections were deparaffinized and rehydrated, and
endogenous peroxidase was inhibited with 0.3% H2O2 meth-
anol. For antigen retrieval, slides were boiled in 0.01 M, pH
6.0 sodium citrate buffer for 15 minutes in a microwave oven.
After blocked with the 5% normal goat serum, primary
antibody (goat anti-MTA1, Santa Cruz Biotechnology, Santa
Cruz, CA) in blocking buffer (1:150) was applied, and the
slides were incubated at 4°C overnight. After incubation with
biotinylated secondary antisera, the streptavidin–biotin com-
plex/horseradish peroxidase was applied. Finally, the visual-
ization signal was developed with 3,3-diaminobenzidine
tetrahydrochloride, and the slides were counterstained in
hematoxylin. Negative controls had the antibody replaced by
phosphate-buffered saline (PBS).
Evaluation of Immunohistochemical Staining
The nuclear staining of MTA1 in tumor tissue was
scored by applying a semiquantitative immunoreactivity scor-
ing (IRS) system, as reported elsewhere.20 Concomitant cy-
toplasmic staining was not counted. Category A documented
the intensity of immunostaining as 0 (no immunostaining), 1
(weak immunostaining), 2 (moderate immunostaining), and 3
(strong immunostaining). Category B documented the per-
centage of immunoreactive cells as 0 (none), 1 (10%), 2
(10–50%), 3 (51–80%), and 4 (80%). Multiplication of
categories A and B resulted in an IRS ranging from 0 to 12
(negative[IRS, 0] versus weak [IRS, 1–4] versus moderate
[IRS, 5–8] versus strong [IRS, 9–12])for each tumor. Both
percent positivity of cells and staining intensity were decided
in a double-blinded manner. Interobserver and intraobserver
variability was negligible. Tumors with moderate or strong
expression (IRS 4) were considered to show MTA1 over-
expression, whereas tumors with negative or weak expression
(IRS 4) were considered to show MTA1 downexpression.
Cell Lines and Cell Culture Conditions
The human lung cancer cell line 95D was purchased from
the cell bank of Chinese Academy of Sciences and cultured in
RPMI 1640 medium (Gibco, Grand Island, NY) supplemented
with 10% fetal bovine serum and 100 U/ml penicillin/strepto-
mycin in a 5% CO2 humidified atmosphere at 37°C.
MTA1 Small Interfering RNA Transfection
Cells were seeded onto a 6-well plate 16 hours before
transfection. In each well, 10 L of MTA1 small interfering
RNA (GACCCTGCTGGCAGATAAA)21 or empty vector and
10 L of Lipofectamine 2000 (Invitrogen) were added to Opti-
MEM and mixed gently and added to the plates. The plate was
incubated for 48 hours until it was ready for further assay.
Real-Time PCR Analysis for MTA1 mRNA
Total RNA from cells was extracted using Trizol re-
agent (Invitrogen) according to the manufacturer’s instruc-
tions. DNase-I-treated total RNA (1g) was used as start-
ing material, to which 1 L (1g/l) of oligo (dT) primer
was added, and diethypyrocarbonate-treated water was added
to the total volume of 11 L. The RNA mixes were heated at
65°C for 5 minutes and then chilled on ice. To each RNA
mix, the following components were added: 4 L of 5
first-strand buffer, 2 L of 0.1 M dithiothreitol, 1 L of
10 mM deoxyribonucleotide triphosphate, and 1 L of ribo-
nuclease inhibitor. The samples were incubated at 42°C for 2
minutes, followed by addition of 200 U of Superscript II and
incubation at 42°C for 50 minutes. The reaction was inacti-
vated at 70°C for 5 minutes. The following primers were used
for amplification of MTA1: sense primer, 5-GAAATATG-
GTGGCTTGAAAAT-3 and antisense primer, 5-ACTTTG-
GTGGGGTAGGACTTC-3. -actin was amplified as an
internal control using sense primer, 5-CGTGGGCCGC-
CCTAGGCA-CCA-3 and antisense primer, 5-TTGGCT-
TAGGGTTCAGGGGGG-3. Real-time PCR was performed
using SYBR Green PCR kit(s) following the manufacturer’s
protocol. The annealing temperature was 56°C for 40 sec-
onds. The relative quantification is determined using the
2Ct method.22
Western Blot Analysis for MTA1 Protein
Cells were washed twice with cold PBS and lysed on
ice in RIPA buffer (1 PBS, 1% NP40, 0.1% sodium
dodecyl sulfate, 5 mM EDTA, 0.5% sodium deoxycholate,
and 1 mM sodium orthovanadate) with protease inhibitors.
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Protein lysates were resolved on 6% sodium dodecyl
sulfate polyacrylamide gel, electrotransferred to polyvi-
nylidene fluoride membranes (Immobilon P; Millipore,
Bedford, MA), and blocked in 5% nonfat dry milk in
Tris-buffered saline, pH 7.5 (100 mM NaCl, 50 mM Tris,
and 0.1% Tween-20). Membranes were immunoblotted
overnight at 4°C with anti-MTA1 polyclonal antibody
(Santa Cruz Biotechnology, SantaCruz, CA), and anti–-
actin antibody (Santa Cruz Biotechnology), followed by
their respective horseradish peroxidase– conjugated sec-
ondary antibodies. Signals were detected by enhanced
chemiluminescence (Pierce, Rockford, IL).
Statistical Analyses
Statistical analysis was performed using SPSS 13.0
software. A 2 test was used to analyze the MTA1 protein
expression in different groups. Survival curves were calcu-
lated using the Kaplan-Meier method and were analyzed
using the log-rank test. The prognostic significance of various
factors was also determined by univariate and multivariate
analyses using the Cox proportional hazard regression model.
The statistical significance was defined as p  0.05.
RESULTS
Expression of MTA1 in NSCLC and Adjacent
Nonneoplastic Lung Tissues
On the tissue microarray, MTA1 was overexpressed in
39 (61.0%) NSCLCs but only in six (9.4%) adjacent nonneo-
plastic lung tissues (p  0.001). The normal alveolar epithe-
lium exhibited negative or weak expression of MTA1; how-
ever, the normal bronchiolar epithelium exhibited moderate
or strong expression, Figure 1. The patterns of MTA1 ex-
pression were mixed nuclear/cytoplasmic staining. Similarly,
of the 100 surgical specimens of NSCLC, 67 (67.0%) exhib-
ited overexpression of MTA1, and downexpression was
found in the other 33 (33.0%) cases, Figure 2.
Expression of MTA1 in NSCLC Cell Lines
To investigate whether MTA1 protein expression is
correlated with mRNA expression, the endogenous MTA1
gene silencing in 95D cell was performed through a small
interfering RNA knockdown technique, and the expression of
MTA1 mRNA, and MTA1 protein were detected by real-time
PCR, Western blot, and immunocytochemistry, respectively.
FIGURE 1. Expression of metastasis-associated
protein 1 (MTA1) in tissue microarray samples.
A, Representive images of MTA1 expression in
non-small cell lung cancer (NSCLC) and adja-
cent nonneoplastic lung tissue (40). B, Distri-
bution of the proportion of different expression
levels of MTA1. The thick arrow indicates the
normal bronchiolar epithelium, and the thin
arrow indicates the normal alveolar epithelium.
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Results showed that both MTA1 protein expression and
MTA1 mRNA expression were significantly decreased in the
transfected 95D cell, Figure 3.
Correlation Between MTA1 Expression and
Clinicopathological Features
Table 1 shows the correlation of MTA1 protein expres-
sion with clinical and pathologic features. MTA1 protein
level in stage III/IV NSCLC was significantly higher than the
level in stage I/II NSCLC (p  0.002). Higher MTA1
expression levels were associated with lymph node metastasis
(p  0.013). There was no correlation between MTA1 ex-
pression level and age, gender, histopathologic type, histo-
logic differentiation, local advance, or distant metastasis.
Evaluating the Prognostic Relevance of MTA1
Expression or Different Clinicopathological
Factors in NSCLC
Univariate Analysis
As the patients in this cohort had variable follow-up
times between 1.4 and 59.3 months, the Cox proportional
hazards model and single-parameter analysis was used to
determine the prognostic significance of each of the different
FIGURE 2. Representative images of non-
small cell lung cancer (NSCLC) clinical sam-
ples staining (A) absent (200), (B) weak
(200), (C) moderate (200), and (D)
strong (200) for metastasis-associated pro-
tein 1 (MTA1) expression.
FIGURE 3. Expression analysis of
metastasis-associated protein 1
(MTA1) mRNA and protein in non-
small cell lung cancer (NSCLC) cell
lines by (A) real-time PCR, (B) West-
ern blot, and (C) immuocytochemis-
try (200). CTL, no-treatment con-
trol; NC, 95D cells transfected with
empty vector; MTA1-si, 95D cells
transfected with MTA1 small inter-
fering RNA.
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clinicopathological factors and MTA1 expression. As shown
in Table 2, age, gender, histopathologic type, and histologic
differentiation did not significantly predict poor overall sur-
vival. In contrast, MTA1 overexpression (p  0.004), local
advance (p  0.001), lymph node metastasis (p  0.001),
distant metastasis (p  0.001), and clinical stage (p  0.000)
significantly predicted decreased overall survival. More spe-
cifically, the mean overall survival time of patients with
MTA1 overexpression in NSCLC was 27.8 months (95%
confidence interval  23.0–32.7), whereas the mean overall
survival time of patients with MTA1 downexpression was
41.8 months (95% confidence interval  34.8–48.7), as
shown in Figure 4A.
We also analyzed the prognostic value of MTA1 ex-
pression in selective patient subgroups stratified according to
the histopathologic type. In lung squamous cell carcinoma,
patients with a high level of expression of MTA1 had a
significantly shorter overall survival compared with patients
with a low level of expression of MTA1 (n  44; log rank,
p  0.022; Figure 4B). In lung adenocarcinoma, although a
trend that differences in prognosis between patients with low
or high expression of MTA1 was found, there was no statis-
tically significant difference (n  38; log rank, p  0.165;
Figure 4C). Thus, MTA1 might be a valuable prognostic
marker for patients with lung squamous cell carcinoma.
Multivariate Analysis
To determine the smallest number of parameters that
could jointly predict disease recurrence in our cohort of patients,
the Cox proportional hazard model and stepwise selection anal-
TABLE 1. Correlation of MTA1 Protein Expression and Clinicopathological Characteristics
Characteristics Total
MTA1 Expression
p 2Low, n (%) High, n (%)
Sex 0.728 0.121
Male 63 20 (31.7) 43 (68.3)
Female 37 13 (35.1) 24 (64.9)
Age (yr) 0.572 0.320
50 85 29 (34.1) 56 (65.9)
50 15 4 (26.7) 11 (73.3)
Histopathologic type 0.357 4.379
Squamous cell carcinoma 44 13 (29.5) 31 (70.5)
Adenocarcinoma 38 12 (31.6) 26 (68.4)
Large cell carcinoma 4 3 (75.0) 1 (25.0)
Adenosquamous carcinoma 9 4 (44.4) 5 (55.6)
NSCLC NOS 5 1 (20.0) 4 (80.0)
Histological differentiation 0.284 5.030
Well differentiateda 28 9 (32.1) 19 (67.9)
Moderately differentiated 19 9 (47.4) 10 (52.6)
Poorly differentiatedb 26 10 (38.5) 16 (61.5)
More than one grade of differentiation 24 4 (16.7) 20 (83.3)
NS 3 1 (33.3) 2 (66.7)
Adenocarcinoma 0.284 3.795
Well differentiateda 24 8 (33.3) 16 (66.7)
Moderately differentiated 5 3 (60.0) 2 (40.0)
Poorly differentiated 2 0 (0.0) 2 (100.0)
More than one grade of differentiation 7 1 (14.3) 6 (85.7)
Local advance 0.269 1.221
T1,2 75 27 (36.0) 48 (64.0)
T3,4 25 6 (24.0) 19 (76.0)
Lymph node metastasis 0.013 6.180
N0 52 23 (44.2) 29 (55.8)
N1,2,3 48 10 (20.8) 38 (79.2)
Distant metastasis 0.143 2.143
M0 91 32 (35.2) 59 (64.8)
M1 9 1 (11.1) 8 (88.9)
Clinical stage 0.002 9.540
I/II 57 26 (45.6) 31 (54.4)
III/IV 43 7 (16.3) 36 (83.7)
a Bronchioloalveolar carcinoma was included in well differentiated.
b Large cell carcinoma was included in poorly differentiated.
MTA1, metastasis-associated protein 1; NSCLC, non-small cell lung cancer; NOS, not otherwise stated; NS, not significant.
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FIGURE 4. A, Kaplan-Meier survival analysis of overall survival in all patients. B, patients with squamous cell carcinoma, and
(C) patients with adenocarcinoma according to metastasis-associated protein 1 (MTA1) expression. The log-rank test was used
to calculate p values.
TABLE 2. Univariate and Multivariate Analyses of Individual Parameters for Correlations
with Survival Rate: Cox Proportional Hazards Model
Parameters
Univariate Multivariate
p HR 95% CI p HR 95% CI
Age 0.612 0.830 0.404–1.705
Gender 0.208 0.698 0.398–1.222
Histopathologic type 0.326 0.912 0.759–1.096
Histological differentiation 0.181 1.167 0.931–1.462
Local advance 0.001 2.573 1.478–4.479 0.015 2.029 1.144–3.599
Lymph node metastasis 0.001 2.455 1.423–4.235 0.498
Distant metastasis 0.001 3.553 1.656–7.626 0.059
Clinical stage 0.000 3.283 1.908–5.646 0.000 2.902 1.660–5.074
MTA1 expression 0.004 2.452 1.324–4.543 0.108
MTA1, metastasis-associated protein 1; HR, hazard radio; CI, confidence interval.
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ysis were used. When all parameters with significant prognostic
impact in univariate analysis (i.e., local advance, lymph node
metastasis, distant metastasis, clinical stage, and MTA1 expres-
sion) were included in the model, only local advance (p 0.015,
hazard ratio  2.03) and clinical stage (p  0.000, hazard
ratio  2.90) reached statistical significance in predicting de-
creased overall survival.
DISCUSSION
NSCLC is one of the most deadly human carcinomas
even with improved diagnosis and compositive therapy, and
the prognosis of NSCLC remains dismal. Metastasis is the
major cause of treatment failure in patients with NSCLC. Its
molecular mechanisms are still not clear and are under
intensive investigations. So, exploring the relationship be-
tween novel gene functions and metastasis of lung cancer is
important for enriching our understanding of the molecular
mechanisms relative to progression of lung cancer, designing
optimal medication, and improving the clinical prognosis of
lung cancer.
MTA1, a novel candidate metastasis-associated gene, is
known to increase the migration and invasion of various
tumor cells in vitro.23–25 Analysis of various tumor tissues
have also found that overexpression of MTA1 mRNA or
protein is correlated positively with the extent of tumor
invasion or lymph node metastasis.9–15
We observed that MTA1 protein level in NSCLC sam-
ples were significantly higher than the level in their adjacent
nonneoplastic lung tissues. The NSCLC overexpressing
MTA1 protein showed higher rates of lymph node metastasis,
and the MTA1 protein level was significantly higher in
advanced lung cancer. The demonstrated correlation between
MTA1 expression and lymph node metastasis, clinical stage
is in accordance with one previous study by Sasaki et al.26
These indicate that MTA1 might play an important role in the
multistep process of carcinogenesis and progression of
NSCLC, especially in tumor metastasis. MTA1 is a compo-
nent of NuRD complexes. MTA1 can regulate gene transcrip-
tion by recruiting histone deacetylase and thus plays its
biologic effects.7 In addition, MTA1 may inhibit p53-medi-
ated apoptosis27 and enhance the stability of hypoxia-induc-
ible factor 1 with the result of promoting angiogenesis.28
Our results also suggest that the development of NSCLC may
be accompanied by upregulation of MTA1, but the mecha-
nism of MTA1 upregulation is unclear.
Recently, researches have suggested that MTA1 is
closely associated with frequent postoperative recurrence and
poor survival in patients with hepatocellular carcinoma or
breast cancer.16,17 Our Kaplan-Meier survival analysis also
revealed that high-level MTA1 expression was significantly
linked to a poor prognosis of patients with NSCLC after
surgical resection. This finding may suggest the prognostic
value of MTA1 expression for patients with NSCLC. It is
obvious that the expression of MTA1 in NSCLC is inversely
proportional to the survival time of patients with NSCLC.
The higher the expression of MTA1 protein, the shorter the
survival time for patients with NSCLC. However, although a
significant correlation was found between MTA1 protein
expression, lymph node metastasis, distant metastasis, or
clinical stage and clinical outcome in our univariate analysis
of survival rate, no such correlation was found in the multi-
variate analysis except local advance and clinical stage. So,
MTA1 expression cannot be served as an independent pre-
dictor of prognosis for patients with NSCLC.
In summary, our study evaluated the prognostic signif-
icance of the MTA1 expression in a large number of NSCLC
clinical tissue specimens at protein level by immunohisto-
chemical analysis. The most valuable finding of this study is
that the overall survival of our study cohort was significantly
poorer in high-MTA1 expression cases than in low-MTA1
expression cases. In particular, MTA1 was significantly as-
sociated with poor prognosis in patients with lung squamous
cell carcinoma.
We believe that further molecular, cellular, and animal
model studies on MTA1 gene will provide new clues for
exploring the mechanism of carcinogenesis and tumor pro-
gression in patients with NSCLC and blaze a new way in the
gene-targeted therapy for lung cancer.
ACKNOWLEDGMENTS
Supported by grants from the National High Technol-
ogy Research and Development Program (“863” Program)
of China (no. 2006AA022478) and National Natural Science
Foundation of China (No. 30772530).
REFERENCES
1. Nicolson GL. Cancer metastasis: tumor cell and host organ properties
improtant in metastasis to specific secondary sites. Biochim Biophys
Acta 1988;948:175–224.
2. Manavathi B, Kumar R. Metastasis tumor antigens, an emerging family
of multifaceted master coregulators. J Biol Chem 2007;282:1529–1533.
3. Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear
receptor biology and pathology. Nucl Recept Signal 2007;5:e010.
4. Xue Y, Wong J, Moreno GT, et al. NURD, a novel complex with both
ATP-dependent chromatin-remodelling and histone deacetylase activi-
ties. Mol Cell 1998;2:851–861.
5. Zhang Y, Ng HH, Erdjument-Bromage H, et al. Analysis of the NuRD
subunits reveals a histone deacetylase core complex and a connection
with DNA methylation. Genes Dev 1999;13:1924–1935.
6. Bowen NJ, Fujita N, Kajita M, et al. Mi-2-NuRD: Multiple complexes
for many purposes. Biochim Biophys Acta 2004;1677:52–57.
7. Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis-associ-
ated gene, mta1, differentially expressed in highly metastatic mammary
adenocarcinoma cell lines. cDNA cloning, expression, and protein anal-
yses. J Biol Chem 1994;269:22958–22963.
8. Hofer MD, Tapia C, Browne TJ, et al. Comprehensive analysis of the
expression of the metastasis-associated gene1 in human neoplastic
tissue. Arch Pathol Lab Med 2006;130:989–996.
9. Balasenthil S, Broaddus RR, Kumar R. Expression of metastasis-asso-
ciated protein 1(MTA1) in benign endometrium and endometrial ade-
nocarcinomas. Hum Pathol 2006;37:656–661.
10. Kidd M, Modlin IM, Mane SM, et al. The role of genetic markers-
NAP1L1, MAGE-D2, and MTA1-in defining small-intestinal carcinoid
neoplasia. Ann Surg Oncol 2006;13:253–262.
11. Giannini R, Cavallini A. Expression analysis of a subset of coregulators
and three nuclear receptors in human colorectal carcinoma. Anticancer
Res 2005;25:4287–4292.
12. Hamatsu T, Rikimaru T, Yamashita Y, et al. The role of MTA1 gene
expression in human hepatocellular carcinoma. Oncol Rep 2003;10:
599–604.
13. Toh Y, Ohga T, Endo K, et al. Expression of the metastasis-associated
MTA1 protein and its relationship to deacetylation of the histone H4 in
esophageal squamous cell carcinomas. Int J Cancer 2004;110:362–367.
Journal of Thoracic Oncology • Volume 5, Number 8, August 2010 MTA1 Protein Expression
Copyright © 2010 by the International Association for the Study of Lung Cancer 1165
14. Hofer MD, Kuefer R, Varambally S, et al. The role of metastasis-
associated protein 1 in prostate cancer progression. Cancer Res 2004;
64:825–829.
15. Sasaki H, Yukiue H, Kobayashi Y, et al. Expression of the MTA1
mRNA in thymoma patients. Cancer Lett 2001;174:159–163.
16. Martin MD, Hilsenbeck SG, Mohsin SK, et al. Breast tumors that
overexpress nuclear metastasis-associated 1 (MTA1) protein have high
recurrence risks but enhanced responses to systemic therapies. Breast
Cancer Res Treat 2006;95:7–12.
17. Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is
closely associated with frequent postoperative recurrence and poor
survival in patients with hepatocellular carcinoma. Hepatology 2008;
47:929–936.
18. Travis WD, Brambilla E, Muller-Harmelink HK, et al. Tumors of the
Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
19. Mountain CF. Revisions in the international system for staging lung
cancer. Chest 1997;111:1710–1717.
20. Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65
is associated with activation of nuclear factor-B dependent signaling in
pancreatic cancer and marks a patient population with poor prognosis.
Br J Cancer 2007;97:523–530.
21. Yoo YG, Kong G, Lee MO. Metastasis-associated protein1 enhances
stability of hypoxia-inducible factor-1a protein by recruiting histone
deacetylase 1. EMBO J 2006;25:1231–1241.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.
Methods 2001;25:402–408.
23. Mahoney MG, Simpson A, Jost M, et al. Metastasis-associated protein
(MTA)1 enhances migration, invasion, and anchorage-independent survival
of immortalized human keratinocytes. Oncogene 2002;21:2161–21670.
24. Hofer MD, Menke A, Genze F, et al. Expression of MTA1 promotes
motility and invasiveness of PNAC-1 pancreatic carcinoma cells. Br J
Cancer 2004;90:455–462.
25. Nicolson GL, Nawa A, Toh Y, et al. Tumor metastasis-associated human
MTA1 gene and its MTA1 protein product: role in epithelial cancer
invasion, proliferation and nuclear regulation. Clin Exp Metastasis
2003;20:19–24.
26. Sasaki H, Moriyama S, Nakashima Y, et al. Expression of the MTA1
mRNA in advanced lung cancer. Lung Cancer 2002;35:149–154.
27. Moon HE, Cheon H, Lee MS. Metastasis-associated protein 1 inhibits
p53- induced apoptosis. Oncol Rep 2007;18:1311–1314.
28. Moon HE, Cheon H, Chun KH, et al. Metastasis-associated protein 1 enhances
angiogenesis by stabilization of HIF-1. Oncol Rep 2006;16:929–935.
Zhu et al. Journal of Thoracic Oncology • Volume 5, Number 8, August 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1166
